ArticlePharmaceutics2025

Drug Metabolism and Pharmacokinetic Evaluation of a Novel RNase H2 Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Yang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.